3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
pembrolizumab
14
Cisplatin
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
7
Brachytherapy
7
Bevacizumab
7
Radiotherapy
6
atezolizumab
5
Platinum
5
Paclitaxel
5
Nivolumab
5
Human Papillomavirus DNA Tests
5
Gemcitabine
5
Colposcopy
5
Carboplatin
5
Blood Specimen Collection
5
Radiation
4
Fulvestrant
4
lenvatinib
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Drug Therapy
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tisotumab vedotin
2
spartalizumab
2
palbociclib
2
camrelizumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled